{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T03:08:25Z","timestamp":1788318505142,"version":"build-2803163510"},"reference-count":47,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.cmi.2024.09.015","type":"journal-article","created":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T16:32:27Z","timestamp":1727281947000},"page":"24-28","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Prevention and treatment of bacterial infections in patients with haematological cancers and haematopoietic stem cell transplantation: headways and shortcomings"],"prefix":"10.1016","volume":"31","author":[{"given":"Ahmet G\u00f6rkem","family":"Er","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah Tarik","family":"Aslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malgorzata","family":"Mikulska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Akova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2024.09.015_bib1","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/imr.12563","article-title":"The intestinal microbiota: antibiotics, colonization resistance, and enteric pathogens","volume":"279","author":"Kim","year":"2017","journal-title":"Immunol Rev"},{"key":"10.1016\/j.cmi.2024.09.015_bib2","first-page":"CD004386","article-title":"Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy","volume":"1","author":"Gafter-Gvili","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"Suppl.\u00a05","key":"10.1016\/j.cmi.2024.09.015_bib3","doi-asserted-by":"crossref","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","article-title":"Management of febrile neutropaenia: ESMO clinical practice guidelines","volume":"27","author":"Klastersky","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cmi.2024.09.015_bib4","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1200\/JCO.18.00374","article-title":"Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA Clinical Practice Guideline Update","volume":"36","author":"Taplitz","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cmi.2024.09.015_bib6","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1002\/cam4.2395","article-title":"Efficacy of antibiotic prophylaxis in patients with cancer and hematopoietic stem cell transplantation recipients: a systematic review of randomized trials","volume":"8","author":"Egan","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.cmi.2024.09.015_bib7","first-page":"20","article-title":"Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines","volume":"76","author":"Mikulska","year":"2018","journal-title":"J\u00a0Infect"},{"key":"10.1016\/j.cmi.2024.09.015_bib8","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00277-020-04297-8","volume":"100","author":"Christopeit","year":"2021","journal-title":"Ann Hematol"},{"key":"10.1016\/j.cmi.2024.09.015_bib9","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1159\/000535119","article-title":"Fluoroquinolone prophylaxis during conventional chemotherapy or hematopoietic stem cell transplantation for acute leukemia\u2014pros and cons","volume":"147","author":"Hoffman","year":"2024","journal-title":"Acta Haematol"},{"key":"10.1016\/j.cmi.2024.09.015_bib10","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.idc.2019.01.001","article-title":"Chemotherapy and beyond: infections in the era of old and new treatments for hematologic malignancies","volume":"33","author":"Atkins","year":"2019","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.cmi.2024.09.015_bib11","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/s12879-023-08218-8","article-title":"Clinical and microbiological profiles in post-chemotherapy neutropenic fever in hematological malignancy: Exploration of clinical phenotype patterns by two-step cluster analysis","volume":"23","author":"Chan","year":"2023","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.cmi.2024.09.015_bib12","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41579-021-00639-z","article-title":"Infectious disease in an era of global change","volume":"20","author":"Baker","year":"2022","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.cmi.2024.09.015_bib13","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13756-017-0208-x","article-title":"The threat of antimicrobial resistance in developing countries: causes and control strategies","volume":"6","author":"Ayukekbong","year":"2017","journal-title":"Antimicrob Resist Infect Control"},{"key":"10.1016\/j.cmi.2024.09.015_bib14","doi-asserted-by":"crossref","first-page":"e277","DOI":"10.1016\/j.ijid.2010.12.010","article-title":"Clinical impact of fluoroquinolone prophylaxis in neutropenic patients with hematological malignancies","volume":"15","author":"Chong","year":"2011","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.cmi.2024.09.015_bib15","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/ejh.12345","article-title":"Clinical and microbiological impact of discontinuation of fluoroquinolone prophylaxis in patients with prolonged profound neutropenia","volume":"93","author":"Verlinden","year":"2014","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.cmi.2024.09.015_bib18","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1093\/cid\/ciab404","article-title":"Colonization with fluoroquinolone-resistant Enterobacterales decreases the effectiveness of fluoroquinolone prophylaxis in hematopoietic cell transplant recipients","volume":"73","author":"Satlin","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.09.015_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2022.1045497","article-title":"Gut microbiota in acute leukemia: current evidence and future directions","volume":"13","author":"Zhou","year":"2022","journal-title":"Front Microbiol"},{"key":"10.1016\/j.cmi.2024.09.015_bib20","doi-asserted-by":"crossref","first-page":"i6","DOI":"10.1093\/jac\/dky530","article-title":"Impact of antimicrobial therapy on the gut microbiome","volume":"74","author":"Bhalodi","year":"2019","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2024.09.015_bib21","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1038\/s41409-020-0811-y","article-title":"Infectious diseases working party (IDWP) of the European group for blood and marrow transplantation group (EBMT). Current antimicrobial practice in febrile neutropenia across Europe and Asia: the EBMT infectious disease working party survey","volume":"55","author":"Verlinden","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.cmi.2024.09.015_bib22","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.3324\/haematol.2013.091025","article-title":"European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia","volume":"98","author":"Averbuch","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.cmi.2024.09.015_bib23","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1200\/JCO.2013.51.6963","article-title":"Results of a multicenter, controlled, randomized clinical trial evaluating the combination of piperacillin\/tazobactam and tigecycline in high-risk hematologic patients with cancer with febrile neutropenia","volume":"32","author":"Bucaneve","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cmi.2024.09.015_bib24","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00045-21","article-title":"Impact of the inclusion of an aminoglycoside to the initial empirical antibiotic therapy for Gram-negative bloodstream infections in hematological neutropenic patients: a propensity-matched cohort study (AMINOLACTAM study)","volume":"65","author":"Albasanz-Puig","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.09.015_bib25","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02292-21","article-title":"Real-life use of ceftolozane\/tazobactam for the treatment of bloodstream infection due to pseudomonas aeruginosa in neutropenic hematologic patients: a matched control study (ZENITH study)","volume":"10","author":"Bergas","year":"2022","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.cmi.2024.09.015_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2021.106335","article-title":"The place of ceftazidime\/avibactam and ceftolozane\/tazobactam for therapy of haematological patients with febrile neutropenia","volume":"57","author":"Clerici","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2024.09.015_bib27","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ijantimicag.2017.06.016","article-title":"Empiric antibiotic protocols for cancer patients with neutropenia: a single-center study of treatment efficacy and mortality in patients with bacteremia","volume":"51","author":"Kleinhendler","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2024.09.015_bib28","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1097\/INF.0000000000002751","article-title":"Cefepime versus cefepime plus amikacin as an initial antibiotic choice for pediatric cancer patients with febrile neutropenia in an era of increasing cefepime resistance","volume":"39","author":"Lee","year":"2020","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.cmi.2024.09.015_bib29","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1093\/jac\/dkad166","article-title":"Advances in antibacterial treatment of adults with high-risk febrile neutropenia","volume":"78","author":"Contejean","year":"2023","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2024.09.015_bib30","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.cmi.2023.10.014","article-title":"Switch to oral antibiotics in Gram-negative bacteraemia: a randomized, open-label, clinical trial","volume":"30","author":"Omrani","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2024.09.015_bib31","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.cmi.2023.07.021","article-title":"Early switch to oral antibiotic therapy in patients with low-risk neutropenic sepsis (EASI-SWITCH): a randomized non-inferiority trial","volume":"30","author":"Coyle","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2024.09.015_bib32","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1473-3099(23)00686-2","article-title":"Efficacy and safety of a structured de-escalation from antipseudomonal \u03b2-lactams in bloodstream infections due to Enterobacterales (SIMPLIFY): an open-label, multicentre, randomised trial","volume":"24","author":"L\u00f3pez-Cort\u00e9s","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2024.09.015_bib33","doi-asserted-by":"crossref","first-page":"e573","DOI":"10.1016\/S2352-3026(17)30211-9","article-title":"Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (how long study): an open-label, randomised, controlled phase 4 trial","volume":"4","author":"Aguilar-Guisado","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.cmi.2024.09.015_bib34","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.cmi.2019.01.005","article-title":"ESCMID-EUCIC clinical guidelines on decolonization of multidrug-resistant Gram-negative bacteria carriers","volume":"25","author":"Tacconelli","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2024.09.015_bib35","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1080\/14787210.2019.1595590","article-title":"The use of predictive scores in the management of patients with carbapenem-resistant Klebsiella pneumoniae infection","volume":"17","author":"Giannella","year":"2019","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.cmi.2024.09.015_bib36","article-title":"Scoping review of risk-scoring tools for early prediction of bloodstream infections caused by carbapenem-resistant Enterobacterales: do we really have a reliable risk-scoring tool?","volume":"6","author":"Aslan","year":"2024","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.cmi.2024.09.015_bib37","doi-asserted-by":"crossref","first-page":"815","DOI":"10.2147\/IDR.S286401","article-title":"Construction of a risk prediction model for subsequent bloodstream infection in intestinal carriers of carbapenem-resistant Enterobacteriaceae: a retrospective study in hematology department and intensive care unit","volume":"14","author":"Wang","year":"2021","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.cmi.2024.09.015_bib38","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.2147\/IDR.S272217","article-title":"Clinical characteristics and risk factors for bloodstream infection due to carbapenem-resistant Klebsiella pneumoniae in patients with hematologic malignancies","volume":"13","author":"Zhang","year":"2020","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.cmi.2024.09.015_bib39","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02494-19","article-title":"Clinical predictive model of multidrug resistance in neutropenic cancer patients with bloodstream infection due to pseudomonas aeruginosa","volume":"64","author":"Gudiol","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.09.015_bib40","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1681\/ASN.0000000000000152","article-title":"Target trial emulation to improve causal inference from observational data: what, why, and how?","volume":"34","author":"Fu","year":"2023","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.cmi.2024.09.015_bib41","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.52250","article-title":"\u201cReal-world\u201d evidence, target trial emulation, and randomized clinical trials-Which data should clinicians rely on when choosing antibiotics?","volume":"7","author":"Paterson","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.cmi.2024.09.015_bib42","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.cmi.2021.12.003","article-title":"What is the evidence base of used aggregated antibiotic resistance percentages to change empirical antibiotic treatment? A scoping review","volume":"28","author":"Auzin","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2024.09.015_bib43","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1080\/13543784.2024.2326028","article-title":"Antibacterial agents active against Gram negative bacilli in phase I, II, or III clinical trials","volume":"33","author":"Paterson","year":"2024","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.cmi.2024.09.015_bib44","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41591-018-0300-7","article-title":"High-performance medicine: the convergence of human and artificial intelligence","volume":"25","author":"Topol","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.cmi.2024.09.015_bib45","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3390\/antibiotics13040307","article-title":"Brave new world of artificial intelligence: its use in antimicrobial stewardship-A systematic review","volume":"13","author":"Pinto-de-S\u00e1","year":"2024","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.cmi.2024.09.015_bib46","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s40121-021-00438-2","article-title":"Machine learning to assess the risk of multidrug-resistant Gram-negative bacilli infections in febrile neutropenic hematological patients","volume":"10","author":"Garcia-Vidal","year":"2021","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.cmi.2024.09.015_bib47","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1080\/14787210.2024.2322445","article-title":"Improving management of febrile neutropenia in oncology patients: the role of artificial intelligence and machine learning","volume":"22","author":"Gallardo-Pizarro","year":"2024","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.cmi.2024.09.015_bib48","doi-asserted-by":"crossref","first-page":"e367","DOI":"10.1016\/S2589-7500(24)00047-5","article-title":"Randomised controlled trials evaluating artificial intelligence in clinical practice: a scoping review","volume":"6","author":"Han","year":"2024","journal-title":"Lancet Digit Health"},{"key":"10.1016\/j.cmi.2024.09.015_bib49","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/s42256-023-00633-5","article-title":"Multimodal data fusion for cancer biomarker discovery with deep learning","volume":"5","author":"Steyaert","year":"2023","journal-title":"Nat Mach Intell"},{"key":"10.1016\/j.cmi.2024.09.015_bib50","doi-asserted-by":"crossref","first-page":"i446","DOI":"10.1093\/bioinformatics\/btz342","article-title":"Deep learning with multimodal representation for pancancer prognosis prediction","volume":"35","author":"Cheerla","year":"2019","journal-title":"Bioinformatics"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X24004476?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X24004476?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T04:09:34Z","timestamp":1767240574000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X24004476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1198743X24004476"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2024.09.015","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevention and treatment of bacterial infections in patients with haematological cancers and haematopoietic stem cell transplantation: headways and shortcomings","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2024.09.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}